← Leaderboards
Vamsidhar Velcheti
Emory University
$2,348,633
Attributed
$5,287,287
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2018–25$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,287,287 · 2
By mechanism
R01$5,287,287 · 2
Top collaborators
- Anant Madabhushi12 shared
- Pingfu Fu2 shared
- Mark Lloyd2 shared
- Kurt A Schalper2 shared
Most similar at Emory University
Same institution · by research overlap
- Qi Long$14,337,177
- Christopher R Flowers$13,825,026
- Douglas C Wallace$28,541,550
- Gregory B. Lesinski$9,344,242
- Joshua Mark Brockman$733,511
Others in their field
Other Emerging Leaders on “Prospective”
- Peter W Pisters · University Of Tx Md Anderson Can Ctr$56,084,949
- Michael Dignam · National Institute Of Allergy And Infectious Diseases$31,845,607
- Stephen F Kry · University Of Tx Md Anderson Can Ctr$28,689,457
- Ellen Gould Chadwick · Harvard University D/B/A Harvard School Of Public Health$25,473,113
- Olwen Hahn · Brigham And Women'S Hospital$23,582,395
- Julie Ake · National Institute Of Allergy And Infectious Diseases$22,000,000
Research focus
ProspectiveTreatment ResponseMorphologyPrognosticTrainingTissuesMeasurementMolecularPatternPredicting ResponseShapesSuccessDiagnosisTextureIndustry PartnerMalignant Neoplasm Of LungCancer PatientComputersCostNon-Small-Cell Lung CarcinomaClinical TrialsClinical Trials Cooperative GroupReportingTumor
Grant awards (12)
Novel Radiomics for Predicting Response to Immunotherapy for Lung Cancer$527,355
R01 · FY2025 · CA
Novel Radiomics for Predicting Response to Immunotherapy for Lung Cancer$506,599
R01 · FY2024 · CA
CHIRP Computerized Histologic Risk Predictor (CHiRP) for Early Stage Lung Cancers$552,153
R01 · FY2023 · CA
Novel Radiomics for Predicting Response to Immunotherapy for Lung Cancer$1
R01 · FY2023 · CA
Novel Radiomics for Predicting Response to Immunotherapy for Lung Cancer$567,039
R01 · FY2022 · CA
CHIRP Computerized Histologic Risk Predictor (CHiRP) for Early Stage Lung Cancers$431,216
R01 · FY2022 · CA
Computerized Histologic Risk Predictor (CHiRP) for Early Stage Lung Cancers$166,988
R01 · FY2022 · CA
Novel Radiomics for Predicting Response to Immunotherapy for Lung Cancer$619,994
R01 · FY2021 · CA
Computerized Histologic Risk Predictor (CHiRP) for Early Stage Lung Cancers$1
R01 · FY2021 · CA
Computerized Histologic Risk Predictor (CHiRP) for Early Stage Lung Cancers$625,797
R01 · FY2020 · CA
Computerized Histologic Risk Predictor (CHiRP) for Early Stage Lung Cancers$619,410
R01 · FY2019 · CA
Computerized Histologic Risk Predictor (CHiRP) for Early Stage Lung Cancers$670,734
R01 · FY2018 · CA